Cipla to Manufacture Gilead's Experimental COVID-19 Drug in India, an Industrial Info Market Brief

---

Indian pharmaceuticals major, Cipla Limited, has signed a non-exclusive licensing agreement to manufacture and sell Gilead Sciences Incorporated's experimental COVID-19 drug - Remdesivir in 127 countries. The re-purposed Ebola drug is being touted as a potential therapy for the coronavirus disease.

As part of the agreement, Cipla is allowed to manufacture the active pharmaceutical ingredient (API) and finished dosage of Remdesivir and market it in 127 countries, including India and South Africa, under Cipla's own brand name.

"Cipla will receive the manufacturing know-how from Gilead Sciences, Inc. to manufacture the API and Finished product at a commercial scale. Cipla's extensive geographical and commercial footprint will help make this therapy accessible to more patients and markets," said a Cipla media release. Industrial Info is tracking 21 Cipla projects worth $112.6 million. Click here for a list.